Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France
<p>Abstract</p> <p>Background</p> <p>During the last decade, oral bisphosphonates (BP) became the most widely prescribed pharmacologic class for post-menopausal osteoporosis. However, many surveys revealed the important issue of poor persistence with those drugs resulti...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-06-01
|
Series: | BMC Health Services Research |
Subjects: | |
Online Access: | http://www.biomedcentral.com/1472-6963/11/151 |